Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IN-PASC
NCT05350774Phase 2Enrolling by invitation
- Sponsor
- National Institute of Neurological Disorders and Stroke
- Start
- Jul 2023
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
A Phase 2 trial of intravenous immunoglobulin G in post-acute sequelae of SARS-CoV-2 infection (PASC), sponsored by National Institute of Neurological Disorders and Stroke. Started Jul 2023; status: enrolling by invitation.
02
Drugs
intravenous immunoglobulin G
03
Conditions
post-acute sequelae of SARS-CoV-2 infection (PASC)
Beyond the preview
Go deeper on NCT05350774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05350774.